Allied Minds portfolio company OcuTerra Therapeutics has secured $14.6m in funding.

OcuTerra Therapeutics, a US-based ophthalmology drug developer based on research at Harvard University, has completed a $14.6m series B round.
Investors in the round have not been identified.
Founded in 2011 as SciFluor Life Sciences, OcuTerra is working on a treatment, OTT166, for diabetic retinopathy, a condition affecting the back of the eye. It is a subsidiary of commercialisation firm Allied Minds.
The series B capital will support a phase 2 trial of OTT166.
OcuTerra previously raised $30m from unnamed investors in April 2015, after Allied Minds had supported a $5m series A round in August 2011.

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
email
Linked in